Latest Articlesddd
The Week in Review #10 NO CONSPIRACY THEORIES - But this is what’s happening - In …
EXELIXIS For Exelixis’ excellent news, please read our latest article, "Exelixis’ (EXEL) Exceptional Financial Results and …
Cabozantinib Net Revenue for Q3 is $96.4 million. Total Revenue of $152.5 million Net Income of $81.4 million, Diluted …
Amgen (AMGN) and Kirin Holdings (Kirin) announced an agreement upon, which Kirin-Amgen, a joint venture between the two …
The Week in Review #9 KNOCKING DOWN THE BIOTECH STOCKS - Knocking down the biotech companies’ stocks …
Prohost Letter #414 GIANTS & DWARFS - We believe it’s a useful idea bringing The Week …
Agenus (AGEN) announced that The Food and Drug Administration (FDA) granted marketing authorization to GlaxoSmithKline's (GSK) …
As expected by those who welcome good news from publicly-traded firms, the Food and Drug Administration …
Spectrum Pharmaceuticals (SPPI) announced an oral presentation of interim data from a Phase 2 clinical study …
Two game changing news has come together on October 16, 2017, both indicating that Exelixis (EXEL) …
The Week in Review #8 Potential biotech winners inspired through COLLABORATION - When successful top-tier drug …
Yes, indeed, the FDA Advisory Committee Unanimously Recommends Approval of Investigational LUXTURNA™ (voretigene neparvovec) for Patients …
Good news emanating from late phase trials by development-stage firms is always refreshing for Prohost, especially …
–The Agreement Covers the Development of Investigational Plasma Kallikrein Inhibitors for Diabetic Macular Edema (DME) – Upfront Fee …
The Week in Review #7 A lot more happened in the past week regarding improving the …
On November 2, 2017 Mannkind (MNKD) announced that the FDA has approved an update to its …
MOTIF BIO Antibiotic Motif Bio’s (MTFB) antibiotic drug Iclaprim met the Phase 3 Revive-2 trial’s primary endpoints …
Realizing the dream of approval of a small biotech’s lead drug would usually lead a small …
The Week in Review #6 A lot has happened in the past week regarding treatments of …
AstraZeneca’s (AZN) checkpoint PD-L1 inhibitor Imfinzi and NewLink Genetics’ (NLNK) IDO inhibitor indoximod will be combined …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
